GCA, also known as temporal arteritis, is the most prevalent form ... stated that the FDA approval offers an alternative treatment option that can help patients achieve sustained remission while ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

GCA, also known as temporal arteritis, is the most prevalent form of vasculitis ... stated that the FDA approval offers an alternative treatment option that can help patients achieve sustained ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA).1 ...

AbbVie’s Rinvoq (upadacitinib) has been approved by the US Food and Drug Administration (FDA) to treat adults with giant cell ...

RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults – Also known as temporal arteritis, GCA is the most common ...

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily, ...